Drug Profile
Research programme: autoimmune disease diagnostics and therapeutics - Enzo Biochem
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Enzo Biochem
- Developer Enzo Biochem; National Eye Institute
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Age-related-macular-degeneration in USA
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 13 May 2013 Early research in Age-related macular degeneration in USA (unspecified route)